Urinary Transglutaminase 2 as a Biomarker for Kidney Allograft Fibrosis

Asan Medical Center

Status: Unknown

Conditions: Kidney Allograft Fibrosis; Kidney Transplant Failure and Rejection

Treatments: Diagnostic Test: observational(urinary biomarker for kidney allograft fibrosis)

Study type: Observational

Funder types: Other

Identifiers

NCT03487861

NRF-2016M3A9E8941330

Details and patient eligibility

About

The aim of this study is to verify the ability of transglutaminase type 2 to predict rejection or chronic allograft nephropathy of renal allograft. On the basis of biomolecular mechanisms aggravating chronic allograft nephropathy, we eventually expect to develop the remedy to prevent chronic allograft nephropathy after kidney transplantation.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• kidney transplant recipients from cadaveric or living donors
• kidney transplant recipients who take immunosuppressants regularly
• kidney transplant recipients who voluntarily agree to participate in this trial

Exclusion criteria

• multiorgan transplant recipients
• kidney transplant recipients with active infection
• kidney transplant recipients with alcohol or drug addiction